Tempus:
Founders Eric Lefkofsky 
Launched in 2015, initial investment was 10 million. Their current revenue is 531.8 million dollars. 
Main focus: : AI-powered precision medicine platform. Provides genomic sequencing and analytics—primarily tumor sequencing, expanding into 
cardiology, radiology, neurology, and depression. Serves 2,400+ hospitals and 19/20 top pharma firms
Future Outlook: Went public June 2024 under NASDAQ TEM, raising ~$410M. Partnering with other companies like Soft bank and getting Ambry 
genetics for 600 million shows that the company is growing rapidly. This shows that it could lead to be one of the leading companies in the 
AI powered sequencing fields. 
